-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Invitation to the event2021 Oncolytic Virus Drug Development Forum will open in Shanghai /MedClub News/--Recently, VBI VACCINES announced that VBI-1901, which uses granulocyte macrophage colony stimulating factor (GM-CSF) as an adjuvant, has been granted Fast Track designation by the FDA for the treatment of first relapse Patients with glioblastoma (GBM)
.
ASCO2021 poster stage 2a tumor response data and overall survival (OS) update data show that patient-specific tumor response data and overall survival (OS) have improved compared with the two historical controls: • Study Group 1: VBI-1901 + Granulocyte-macrophage colony stimulating factor (GM-CSF) 6 months and 12 months OS: 80% (n=8/10) and 60% (n=6/10) 2 cases of partial remission, 2 cases were observed to be stable with a disease control rate of 40% • Study group 2: VBI-1901+GSK's AS01B adjuvant system 6 months OS: 89% (n=8/9) 5 cases were observed to be stable The disease control rate is up to 50%.
Because there are few treatments for patients with recurrent GBM, historical control data show that the overall survival rate of 6 months after monotherapy is about 60%, and the overall survival rate of 12 months is about 30%.
.
"This fast-track designation provides additional medical validation and is a meaningful milestone in our development of VBI-1901, as we are committed to providing clinical benefits to patients who have no available treatment options," VBI's Chief Medical Officer, Medical Dr.
Francisco Diaz Mitoma said, “Based on the encouraging data we have seen so far, we look forward to working more closely with the FDA because we are developing this cancer vaccine immunotherapy candidate drug, hoping to improve the prognosis of adults with recurrent GBM.
.
"▲ VBI's Chief Medical Officer, MD, Francisco Diaz-Mitoma (Source: bing) VBI Vaccines Inc.
(VBI ) is a company driven by the immunology biopharmaceutical company, in pursuit of a powerful disease prevention and treatment
.
By its Innovative methods of virus-like particles (VLP), including proprietary enveloped VLP platform technology, VBI has also developed candidate vaccines that mimic the natural appearance of viruses, aiming to stimulate the innate power system of human immunity
.
VBI is currently working to include type B Hepatitis, coronavirus and cytomegalovirus (CMV), and aggressive cancers including glioblastoma (GBM)
.
VBI product pipeline: ▲Prophylactic vaccine candidates and clinical progress (Image source: vbi)▲Treatment Cancer vaccine candidates and clinical progress (Image source: vbi) Cancer vaccines overcome the bottleneck of traditional therapies.
Tumors in the human body usually evolve after 10 to 20 years.
Each cancer patient usually has many tumors with different characteristics at the same time.
This phenomenon is known as "tumor heterogeneity"
.
due to the heterogeneity of existence, sometimes anti-cancer drugs can kill 90% of human cancer cells, but not 100%, which leads to drug resistance and tumor recurrence
.
Because traditional chemotherapy owe Good, the side effects are too large, so cancer immunotherapy is very interesting
.
The
so-called immunotherapy is to use the specific killing power of the body's own immune cells to accurately eliminate cancer cells
.
One of the mainstream solutions is to modify the patient's own T cells, which is about After the T cells are collected from the blood, they enhance their immunity against malignant tumor cells in vitro, and then return to the patient's body to exert specific tumor treatment effects
.
However, the disadvantage of this method is that it takes longer to culture in vitro cells.
Long, complicated and expensive
.
So scientists began to study whether it is possible to omit the complicated process of in vitro culture so that such T cells can strengthen their recognition ability in the body, and directly contact and kill tumor cells
.
Cancer vaccines came into being.
Cancer vaccines have received attention and development.
Nowadays, in the hot list of cancer immunotherapy, in addition to the highly visible immune checkpoint PD-(L)1 inhibitors and cellular immunotherapy (CAR-T, etc.
) ) In addition, therapeutic cancer vaccines have also shown great potential
.
For more details, click on the QR code to read the reference materials in full: 1.
https:// -for-the-treatment-of-recurrent-gbm/YiMike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix of all media users has reached 160,000+, of which industrial users accounted for Over 50%, about 30% of scientific research and clinical users, and over 5% of users in investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
.
ASCO2021 poster stage 2a tumor response data and overall survival (OS) update data show that patient-specific tumor response data and overall survival (OS) have improved compared with the two historical controls: • Study Group 1: VBI-1901 + Granulocyte-macrophage colony stimulating factor (GM-CSF) 6 months and 12 months OS: 80% (n=8/10) and 60% (n=6/10) 2 cases of partial remission, 2 cases were observed to be stable with a disease control rate of 40% • Study group 2: VBI-1901+GSK's AS01B adjuvant system 6 months OS: 89% (n=8/9) 5 cases were observed to be stable The disease control rate is up to 50%.
Because there are few treatments for patients with recurrent GBM, historical control data show that the overall survival rate of 6 months after monotherapy is about 60%, and the overall survival rate of 12 months is about 30%.
.
"This fast-track designation provides additional medical validation and is a meaningful milestone in our development of VBI-1901, as we are committed to providing clinical benefits to patients who have no available treatment options," VBI's Chief Medical Officer, Medical Dr.
Francisco Diaz Mitoma said, “Based on the encouraging data we have seen so far, we look forward to working more closely with the FDA because we are developing this cancer vaccine immunotherapy candidate drug, hoping to improve the prognosis of adults with recurrent GBM.
.
"▲ VBI's Chief Medical Officer, MD, Francisco Diaz-Mitoma (Source: bing) VBI Vaccines Inc.
(VBI ) is a company driven by the immunology biopharmaceutical company, in pursuit of a powerful disease prevention and treatment
.
By its Innovative methods of virus-like particles (VLP), including proprietary enveloped VLP platform technology, VBI has also developed candidate vaccines that mimic the natural appearance of viruses, aiming to stimulate the innate power system of human immunity
.
VBI is currently working to include type B Hepatitis, coronavirus and cytomegalovirus (CMV), and aggressive cancers including glioblastoma (GBM)
.
VBI product pipeline: ▲Prophylactic vaccine candidates and clinical progress (Image source: vbi)▲Treatment Cancer vaccine candidates and clinical progress (Image source: vbi) Cancer vaccines overcome the bottleneck of traditional therapies.
Tumors in the human body usually evolve after 10 to 20 years.
Each cancer patient usually has many tumors with different characteristics at the same time.
This phenomenon is known as "tumor heterogeneity"
.
due to the heterogeneity of existence, sometimes anti-cancer drugs can kill 90% of human cancer cells, but not 100%, which leads to drug resistance and tumor recurrence
.
Because traditional chemotherapy owe Good, the side effects are too large, so cancer immunotherapy is very interesting
.
The
so-called immunotherapy is to use the specific killing power of the body's own immune cells to accurately eliminate cancer cells
.
One of the mainstream solutions is to modify the patient's own T cells, which is about After the T cells are collected from the blood, they enhance their immunity against malignant tumor cells in vitro, and then return to the patient's body to exert specific tumor treatment effects
.
However, the disadvantage of this method is that it takes longer to culture in vitro cells.
Long, complicated and expensive
.
So scientists began to study whether it is possible to omit the complicated process of in vitro culture so that such T cells can strengthen their recognition ability in the body, and directly contact and kill tumor cells
.
Cancer vaccines came into being.
Cancer vaccines have received attention and development.
Nowadays, in the hot list of cancer immunotherapy, in addition to the highly visible immune checkpoint PD-(L)1 inhibitors and cellular immunotherapy (CAR-T, etc.
) ) In addition, therapeutic cancer vaccines have also shown great potential
.
For more details, click on the QR code to read the reference materials in full: 1.
https:// -for-the-treatment-of-recurrent-gbm/YiMike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix of all media users has reached 160,000+, of which industrial users accounted for Over 50%, about 30% of scientific research and clinical users, and over 5% of users in investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
